Nimity: a complete equity management solution designed for all stakeholders.

SeedBlink Blog

startups And Financing

Advancing gum disease treatment: a conversation with Pierre Tangermann and Dr. Mirko Buchholz, CEO and CSO of PerioTrap


Bianca Iulia Simion

· 3 min read
Advancing gum disease treatment: a conversation with Pierre Tangermann and Dr. Mirko Buchholz, CEO and CSO of PerioTrap
Gain insights into PerioTrap's approach to combating periodontal disease.

Pierre Tangermann brings a wealth of experience to the helm of PerioTrap Pharmaceuticals GmbH, where he serves as CEO and Founder. With a background spanning from academia to business development in leading research institutions like the Fraunhofer Institute for Cell Therapy and Immunology, Pierre's journey reflects a dedication to bridging the gap between scientific innovation and commercial success. Together with Dr. Mirko Buchholz, who brings in years of experience in biotech and served as a group leader at Fraunhofer, the duo manages PerioTrap’s development.

PerioTrap has introduced a novel treatment targeting the bacteria responsible for Periodontitis, a common gum inflammation disorder affecting half of adults. Unlike traditional toothpaste that broadly targets bacteria, potentially disrupting beneficial oral microbes, PerioTrap's substance selectively inhibits harmful bacteria while preserving the healthy oral microbiome.

1. What ‘aha’ moment led to the founding of PerioTrap?

When we saw a specific effect of our compounds on the bacterium confirming our target hypothesis. To us, it then felt like we stumbled upon the needle in the haystack.

2. What was your drive back then? What change did you want to make?

The oral care space hasn’t seen any revolutions in the last years leaving patients with little options to manage their conditions. That’s what we wanted to change with a feasible and affordable solution.

3. How does PerioTrap significantly contribute to addressing the challenges of periodontitis treatment, and what specific market gap does it address?

We develop our products in alignment with the technical and market challenges. Not only is it a complex disease but due to the high out-of-pocket contributions there is a high cost pressure of treatments. So we focus on patient and user journeys to make products that are easily appliable to maximize adherence but that are also cost-effective in manufacturing.

4. How do you scale your business, driving financial success?

We have a strong partnering approach with market leaders in the fields. Once launched, our products can get ad-hoc access to millions of users and patients.

5. How does PerioTrap guide and empower clinicians to make informed decisions when adopting your periodontitis treatment solutions?

As a spin-off from leading European research institutions, our developments were science-driven from the beginning. We keep pursuing this strategy by working with the world’s most renowned clinicians in the field. Profound publications will help forge new paradigms in periodontitis management.

6. How do you envision the company's future growth within the pharmaceutical sector, particularly in the field of periodontitis treatment?

The pharmaceutical pathway is only one route we’re addressing, currently with a product with known treatment codes. In the dental field pharmaceutical products are rare, so we would like to be considered as a leader in this particular field.

7. What are potential exit scenarios for investors supporting PerioTrap?

We have a distinguished IP strategy to support industry-specific exits of assets which we envision after market proof-of-concepts.

8. Do you have a mentor or person you admire in the tech industry?

Haha, well. I don’t have a specific role model. I consider everyone an ally and the community is so supportive which itself admires me.

9. Why should investors consider being part of PerioTrap's journey?

Being involved in genuine innovations in the management of one of the world's most prevalent and persistent diseases is simultaneously fulfilling from a humanitarian standpoint and economically lucrative.

Explore the opportunity on SeedBlink.

Subscribe to our newsletter

The place from where you get all information and details about the European startup ecosystem, technology trends, the VC and business angels world, investment opportunities, and news.


SeedBlink S.A. is registered in the Register of the Romanian Financial Supervisory Authority (ASF), under number PJR28FSFPR/400001, as of 03.11.2022 with an EU passport as per European Securities and Market Authority (ESMA) register of crowdfunding services providers.


Peeked at the footer? Don't let your curiosity end here and explore more!

Investing in start-ups involves risks, including loss of capital, illiquidity, dilution, lack of dividends. It is suitable only for investors capable of evaluating and bearing those risks. In any event, it should be done only as part of a diversified portfolio (meaning a portfolio in which investment in start-ups represents only a fraction of the total investments or assets). Before investing please read the risk warnings available at as well as the risks related provisions of the investment facilitation agreement that will be provided to you for the relevant round. SeedBlink is not responsible for any information provided by the start-ups, even if distributed through or by SeedBlink. SeedBlink does not endorse any start-up for investment nor does it advise you on the merits of your investment. Seedblink does not provide to you any other advisory services. The decision to invest is yours only. If you require help in evaluating a decision to invest, you should consult a professional adviser. The messages and documentation you receive from SeedBlink or the start-ups have been neither verified nor approved by the Romanian or the European authorities. Nothing in this message shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful.